Results 61 to 70 of about 6,336 (192)

Distal Agrin (AGRN) Congenital Myasthenic Syndrome With Mitochondrial Dysfunction

European Journal of Neurology, Volume 33, Issue 7, July 2026.
ABSTRACT Background Agrin‐congenital myasthenic syndrome (AGRN‐CMS) is a rare, heterogeneous genetic disorder of the neuromuscular transmission that can present from infancy to adulthood. The clinical phenotype includes distal weakness mimicking distal myopathies.
Mariana Manoel Oku, Zhiyv Niu, Duygu Selcen, William J. Litchy, Margherita Milone   +4 more
wiley   +1 more source

Marathons and myasthenia gravis: a case report

BMC Neurology, 2018
Background The cardinal symptoms of auto-immune myasthenia gravis are fatigue and weakness. Endurance events such as marathon running would seem incompatible with this chronic disease. Many patients stop sport altogether.
Simone Birnbaum, Tarek Sharshar, Bruno Eymard, Marie Theaudin, Pierre Portero, Jean-Yves Hogrel   +5 more
doaj   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1106-1117, June 2026.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Disease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 615-629, June 2026.
ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail, Lynn Warner, Stacey T. Gray, Claire Hopkins, Peter H. Hwang, Sarah K. Wise, Katie M. Phillips, Ahmad R. Sedaghat   +7 more
wiley   +1 more source

Miasthenia gravis in pediatric age

Acta Médica del Centro, 2008
Background: Myasthenia gravis is an autoimmune disorder characterized by fluctuating muscle weakness and fatigue of different muscle groups, secondary to a synaptic transmission alteration caused by the blockade and destruction of the acetylcholine ...
Liubka María Pérez Mederos, María Ofelia Hernández Oliver, Cecilio González Benavides, José Manuel González Santos   +3 more
doaj  

Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Brain and Behavior, Volume 16, Issue 6, June 2026.
ROZ 10 mg/kg ranked best for reducing MG‐ADL. BAT 680 mg significantly reduced QMG and ranked best. BAT 340 mg had the highest probability of reducing the MGC score. ECU significantly decreased MG‐QoL 15r and ranked best. BEL 10 mg/kg had the highest likelihood of reducing adverse events.
Muhammad Hassan Waseem, Zain ul Abideen, Minahil Iqbal, Saniya Ishtiaq, Pawan Kumar Thada, Adam A. Dmytriw   +5 more
wiley   +1 more source

Case Report: Recurrent Guillain–Barré Syndrome in a 56‐Year‐Old Male

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Recurrent Guillain–Barré syndrome (GBS) is an uncommon variant of immune‐mediated polyradiculoneuropathy. We report a 56‐year‐old male who had two distinct episodes of acute inflammatory demyelinating neuropathy within the span of 3 months. The first episode presented with an episode of ascending paralysis and areflexia, with nerve conduction ...
Farah Sadiq, Shayan Nawaz, Moeez Ahmad Saeed, Fahad Bilal, Hafiza Manahil Majeed, Wasfa Shafiq, Kashaf Imtiaz, Muhammad Husnain Ahmad, Ali Gohar   +8 more
wiley   +1 more source

Pembrolizumab‐Induced Myositis: Diagnostic and Therapeutic Challenges From Two Case Reports and a Narrative Review

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Pembrolizumab, an anti‐PD‐1 immune checkpoint inhibitor, has transformed the treatment of multiple solid tumors. However, it can rarely cause immune‐related myositis, which may involve limb, bulbar, and respiratory muscles, posing a risk of severe morbidity and mortality. Early recognition and management are essential. We report two
Francesca Rifaldi, Niccolò Leandro Alessio, Francesca Caspani, Elena Bolzacchini, Monica Giordano, Paolo Pedrazzoli   +5 more
wiley   +1 more source

Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Tacrolimus monotherapy yields high remission in adult‐onset MG, especially in new‐onset or younger patients. Relapse is linked to low tacrolimus concentration and rapid tapering. Hyperglycemia was the most common ADR. Long‐term use may increase cancer risk.
Zhangyan Geng, Yuting Jiang, Nairong Xie, Wenjia Zhu, Hai Chen, Yaye Wang, Haoran Liu, Qinyao Liu, Congwen Lv, Yu Qian, Yan Lu, Li Di, Min Wang, Min Xu, Xinmei Wen, Bingchuan Xie, Yuwei Da   +16 more
wiley   +1 more source

An Atypical Case of Myasthenia Gravis: Purely Bulbar in a Young Male

McGill Journal of Medicine, 2020
Myasthenia Gravis (MG), an uncommon autoimmune syndrome caused by the failure of neuromuscular transmission, results from bind- ing of autoantibodies to proteins that are involved in signaling at the neuromuscular junction (1).
Muhammad Amer Saleem, Faizan Pervaiz, Anum Yousaf, Muhammad Amer Saleem   +3 more
doaj